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Research
Parkinson’s disease (PD) is the second most 
common neurodegenerative disorder. The 
likelihood of developing PD increases with 
age. PD is rare before age 50. The average age 
of onset is in the mid­ to late 60s (Bower et al. 
1999; de Rijk et al. 1995; Marras and Tanner 
2002; Van den Eeden et al. 2003). As the 
U.S. population ages, prevalence of this dis­
abling disorder is expected to rise dramatically 
(Dorsey et al. 2007). Unfortunately, few valid 
data that address changes in PD incidence 
or prevalence over time are available. In fact, 
active case­finding efforts in communities 
detect as many as 10–40% of cases of PD for 
the first time, suggesting that underestima­
tion of PD prevalence is common (de Pedro­
Cuesta 1991; de Rijk et al. 1997).
The symptoms of PD are slowly progres­
sive. Well­recognized clinical features of PD 
are slowed movements, tremor, rigidity, and 
difficulties with gait and balance. However, 
other features commonly occur, including 
changes in olfaction, autonomic function, 
cognitive function, affect, sleep, and energy 
level (Alves et al. 2005; Burn et al. 2006; 
Pfeiffer 1998; Stern et al. 1994). 
In PD, specific neuronal populations 
degenerate. Neurodegeneration occurs in con­
cert with the deposition of aggregates of the 
protein alpha synuclein in neuronal cell bod­
ies and processes (Spillantini et al. 1998). The 
classical focus has been on dopamine­releasing 
cells in the substantia nigra, because dopamine 
replacement can partially correct some of the 
motor features of PD. It has long been known, 
however, that many other neuronal popula­
tions are also affected in PD. Recently, converg­
ing epidemiologic and pathologic data suggest 
that years or even decades before the onset of 
these classical features of PD, neurons outside 
of the central nervous system may be injured 
(Abbott et al. 2005, 2007; Braak et al. 2004; 
Langston 2006; Ross et al. 2008). If this is cor­
rect, current concepts of PD will need revision. 
Clarification may provide exciting new oppor­
tunities for treatment and intervention.
In the 1980s, the observation that intra­
venous exposure to 1­methyl­4­phenyl­
1,2,3,6­tetrahydropyridine (MPTP) caused 
parkinsonism in humans offered important 
insights into environmental triggers (Langston 
et al. 1983). Even though relatively uncom­
mon genetic mutations are sufficient to cause 
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Ba c k g r o u n d : Parkinson’s disease (PD) is the second most common neurodegenerative disorder. 
People with PD, their families, scientists, health care providers, and the general public are increas-
ingly interested in identifying environmental contributors to PD risk. 
Me t h o d s : In June 2007, a multidisciplinary group of experts gathered in Sunnyvale, California, 
USA, to assess what is known about the contribution of environmental factors to PD. 
re s u l t s : We describe the conclusions around which they came to consensus with respect to envi-
ronmental contributors to PD risk. We conclude with a brief summary of research needs. 
co n c l u s i o n s : PD is a complex disorder, and multiple different pathogenic pathways and mecha-
nisms can ultimately lead to PD. Within the individual there are many determinants of PD risk, 
and within populations, the causes of PD are heterogeneous. Although rare recognized genetic 
mutations are sufficient to cause PD, these account for < 10% of PD in the U.S. population, and 
incomplete penetrance suggests that environmental factors may be involved. Indeed, interplay 
among environmental factors and genetic makeup likely influences the risk of developing PD. 
There is a need for further understanding of how risk factors interact, and studying PD is likely to 
increase understanding of other neurodegenerative disorders.
ke y w o r d s : cholesterol, coffee, dairy products, diet, dopamine, fatty acids, metals, nonsteroidal 
anti-inflammatory drugs, Parkinson’s disease, pesticides, polychlorinated biphenyls, smoking, 
statins, urate. Environ Health Perspect 117:117–121 (2009).  doi:10.1289/ehp.11702 available via 
http://dx.doi.org/ [Online 26 August 2008]Bronstein et al.
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some cases of PD, twin studies conclude that 
the contribution of genetic makeup to the 
risk of most cases of PD is limited (Tanner 
et al. 1999; Wirdefeldt et al. 2004). Moreover, 
studies of uncommon genetic forms of PD 
have shown that changes in the structure of 
proteins that can lead to neural dysfunction, 
and death can also be caused independently 
by some environmental toxicants (Lee 2003; 
Purisai et al. 2005; Uversky et al. 2001; Vila 
et al. 2000). As a result, a general view has 
evolved that the vast majority of cases of PD 
are caused by environmental factors interact­
ing with genetic makeup.
People with PD, their families, scientists, 
health care providers, and the general public 
are increasingly interested in identifying envi­
ronmental contributors to PD with an eye 
toward not only more effective treatments 
but also prevention. What percentage of cases 
involves preventable causes? What precau­
tionary interventions would be warranted 
and effective, and when must they be imple­
mented? Can individuals destined to develop 
neurologic dysfunction due to PD be identi­
fied before typical motor symptoms manifest? 
The current scientific literature does not 
provide conclusive answers to most of these 
and other relevant questions. But indica­
tions from epidemiology, basic neurobiol­
ogy, and toxicology increasingly support the 
conclusion that a large portion of the risk of 
developing PD may be attributable to envi­
ronmental exposures. Therefore, the risk of 
PD is theoretically reducible to the extent 
that some cases may be preventable. 
Purpose of Conference
Responding to these questions and concerns, 
a multidisciplinary group of experts gath­
ered in Sunnyvale, California, USA, 26–28 
June 2007, to assess what is known about 
the contribution of environmental factors to 
PD. Participants included toxicologists, epi­
demiologists, geneticists, neuroscientists, and 
medical practitioners. They were joined by 
representatives of PD advocacy groups and 
people with PD to review the state of envi­
ronmental health science as it pertains to PD. 
The purposes of the meeting were as follows: 
•	To	review	findings	from	diverse	research	
disciplines concerning environmental factors 
that alone or in combination with genetic 
variables provide a biologic basis of PD 
•	To	identify	conclusions	that	could	be	drawn	
with confidence from existing data 
•	To	identify	plausible	but	uncertain	conclu­
sions
•	To	identify	research	gaps	and	needs	and	
to describe features of a coherent research 
agenda. 
Participants recognized the existence of 
various syndromes that may share some clini­
cal and neurobiologic features with classic PD. 
Sometimes the term “parkinsonism” is used to 
refer to these syndromes. They often involve 
more extensive (or less specific) brain injury 
than is typically seen in classic PD and can 
be degenerative or nondegenerative (e.g., car­
bon monoxide–induced parkinsonism, carbon 
tetrachloride–induced parkinsonism, vascular 
parkinsonism). However, boundaries between 
PD and parkinsonism are evolving concepts. 
For this reason, participants were not asked to 
discuss and come to a consensus definition of 
PD.
Participants did not attempt to rank spe­
cific pathogenic mechanisms with respect to 
their relative importance in PD causation. 
Nonetheless, various combinations of alpha 
synuclein deposition, mitochondrial dys­
function, proteosome dysfunction, oxidative 
stress, and inflammation arose in discussions 
of potential contributors in causal pathways. 
Participants were also not asked to address 
and did not consider a) an exhaustive list of 
toxicants that have been associated with PD 
(examples of toxicants not considered include 
organic solvents, electromagnetic fields); or 
b) factors that may influence the progression 
of PD (as differentiated from causes of onset 
of PD).
Over the course of the meeting, the fol­
lowing core points of consensus were iden­
tified, which we offer in this summary to 
acquaint scientists, medical professionals, pub­
lic health advocates, and policy makers with 
the current state of understanding in the field, 
as seen by conference participants, and to help 
in identifying fruitful research strategies. 
Findings
Sufficient evidence of a causal relationship. 
Based on existing evidence, we are confident 
of the following:
•	PD is a complex disorder, and multiple 
different pathogenic pathways and mecha­
nisms can ultimately lead to PD. Within 
the individual there are multiple determi­
nants of PD risk, and within populations 
the causes of PD are heterogeneous. The 
interplay among environmental factors and 
genetic makeup likely influences the risk of 
developing PD (Chade et al. 2006; Warner 
and Schapira 2003). 
•	PD risk increases with age (Bower et al. 
1999; de Rijk et al. 1995; Van den Eeden 
et al. 2003; Zhang et al. 2003). 
•	Studying PD is likely to increase understand­
ing of other neurodegenerative disorders.
•	Rare recognized genetic mutations are suf­
ficient to cause PD (Singleton et al. 2003; 
Warner and Schapira 2003). However, col­
lectively these genetic mutations account 
for < 10% of PD in the U.S. population. 
Moreover, even in these rare instances, 
incomplete penetrance suggests that environ­
mental factors may be involved (Elbaz 2008). 
•	In addition to rare genetic mutations, PD 
or parkinsonism can also rarely be induced 
primarily by exposure to toxicants that 
directly target the area of the brain involved 
in PD. MPTP is an example of such a toxi­
cant (Langston et al. 1983). 
PD risk factors are categorized accord­
ing to the terminology of the Institute of 
Medicine (IOM) for strength of evidence. 
IOM committees sometimes classify the evi­
dence of association between exposure to a 
specific agent and a specific health outcome 
into five previously established categories, as 
set forth below. The group of experts gathered 
in Sunnyvale decided to use these catego­
ries as a means of describing their evaluation 
of the state of the evidence with respect to 
the influence of various factors on PD risk. 
Criteria for inclusion in each category are 
described at the outset. 
Participants felt that these categories for 
describing the strength of evidence pertain­
ing to individual risk factors were useful even 
though not based here on a systematic evi­
dence­based literature review. Risk factors 
were assigned to the various categories based 
on consensus opinion of those attending the 
conference. Moreover, within each category 
there is no attempt to list the entries in any 
particular order. 
Sufficient evidence of an association. In 
this IOM category, evidence from available 
studies is sufficient to conclude that there is 
a positive association. A consistent positive 
association has been observed between expo­
sure to a specific agent and a specific health 
outcome in human studies in which chance 
and bias, including confounding, could be 
ruled out with reasonable confidence. For 
example, several high­quality studies report 
consistent positive associations, and the stud­
ies are sufficiently free of bias, including ade­
quate control for confounding. 
•	Men	are	at	greater	risk	of	PD	than	women	
(Bower et al. 1999; de Rijk et al. 1995; Van 
den Eeden et al. 2003). However, increased 
risk to a disease can occur because of inher­
ently increased susceptibility, increased expo­
sures to causal agent(s), or combinations of 
the two (Wooten et al. 2004). Current evi­
dence is not sufficient to explain with confi­
dence the increased risk in males. 
•	Evidence	is	sufficient	to	conclude	with	con­
fidence that cigarette smokers have a lower 
risk of PD than nonsmokers (Hernan et al. 
2002; Ritz et al. 2007). PD risk may also 
be lower for people who use other tobacco 
products, although the evidence is not 
as extensive or persuasive as for cigarette 
smokers, and conference participants were 
less confident in drawing conclusions. 
•	Evidence	is	also	sufficient	to	conclude	that	
male coffee drinkers have a lower risk of 
PD than females (Ascherio et al. 2004; Ross Consensus statement: Parkinson’s disease and the environment
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et al. 2000). For women coffee drinkers and 
people consuming other caffeinated bever­
ages, evidence is limited, but a similar pat­
tern seems to emerge (Ascherio et al. 2001). 
Conference participants are confident of 
the associations but uncertain about the causal 
relationships or pathways by which smoking 
and coffee consumption might have a neuro­
protective effect. Various biologic mechanisms 
have been proposed. For example, nicotine in 
cigarettes and caffeine in coffee are hypoth­
esized to be agents that may confer a lower 
PD risk. However, noncausal explanations for 
these associations are also plausible (Hernan 
et al. 2002), uncertainties remain, and no con­
sensus has been achieved. Nonetheless, further 
investigation into the biologic mechanisms by 
which female sex, cigarette smoking, and cof­
fee consumption lower PD risk is warranted 
and may result in important insights into the 
etiology and progression of PD. 
Limited suggestive evidence of an associa-
tion. In this IOM category, evidence from 
available studies suggests an association 
between exposure to a specific agent and a spe­
cific health outcome in human studies, but the 
body of evidence is limited by the inability to 
rule out chance and bias, including confound­
ing, with confidence. For example, at least 
one high­quality study reports a positive asso­
ciation that is sufficiently free of bias, includ­
ing adequate control for confounding. Other 
corroborating studies provide support for the 
association, but they were not sufficiently free 
of bias, including confounding. Alternatively, 
several studies of less quality show consistent 
positive associations, and the results are prob­
ably not due to bias, including confounding. 
Available scientific studies suggest an associ­
ation between a number of different factors and 
PD risk. Here, the data are limited but tend to 
point toward a valid association with PD risk. 
Causal mechanisms explaining the associations, 
if they exist, are not well understood. 
•	People	with	higher	levels	of	physical	activity	
have a reduced risk of PD (Thacker et al. 
2008). 
•	Men,	and	possibly	women,	with	higher	
blood urate levels have a reduced risk of PD 
(Davis et al. 1996; Weisskopf et al. 2007).
•	People taking nonsteroidal anti­inflamma­
tory drugs have a lower risk of PD (Powers 
et al. 2008a; Wahner et al. 2007).
•	Men with high dietary intake of dairy prod­
ucts have an increased risk of PD (Chen 
et al. 2002; Park et al. 2005).
•	Farmers and agricultural workers have an 
increased risk of PD (Hertzman et al. 1994; 
Gorell et al. 1998; Tuchsen and Jensen 
2000). Epidemiologic studies often clas­
sify study participants according to their 
occupation and examine for associations 
between occupations and outcomes of inter­
est. In these cases, inferences about potential 
exposures that characterize those occupations 
may be drawn, but they remain as inferences 
and should not be confused with estimates of 
exposure to specific environmental agents. 
•	People exposed to pesticides have an increased 
risk of PD (Dick et al. 2007; Gorell et al. 
1998; Hancock et al. 2008; Kamel et al. 
2007). However, epidemiologic study designs 
may classify study participants according to 
reported exposures to classes of chemicals 
or other agents. In these cases, associations 
between the class of environmental agents 
and outcome of interest may be identified, 
but in most cases specific agents that account 
for the association cannot be further identi­
fied from those data. Meeting participants 
note the evidence suggesting a direct associa­
tion between pesticide exposure and PD risk 
but are unable to draw any conclusions about 
specific agents that may be responsible. 
•	People with traumatic brain injury have an 
increased risk of PD (Bower et al. 2003, 
Dick et al. 2007; Goldman et al. 2006). 
•	Certain variants of genes can modify the 
risk of PD. The risk may be higher or lower 
depending on the variant (Warner and 
Schapira 2003). 
Inadequate/insufficient evidence to deter-
mine whether an association exists. In this 
IOM category, evidence from available studies 
is of insufficient quantity, quality, or consis­
tency to permit a conclusion regarding the 
existence of an association between exposure 
to a specific agent and a specific health out­
come in humans. 
•	People	with	higher	dietary	intake	of	poly­
unsaturated fatty acids have lower risk of 
PD (de Lau et al. 2005).
•	People	with	higher	blood	cholesterol	have	
lower risk of PD (Hu et al. 2008; Simon 
et al. 2007). 
•	Dietary	sources	of	urate	lower	the	risk	of	
PD (Annanmaki et al. 2007; Gao et al. 
2008). 
•	People	taking	statins	are	at	lower	risk	of	PD	
(Becker et al. 2008; Wahner et al. 2008).
•	Postmenopausal	women	taking	exogenous	
estrogen are at reduced risk of PD (Currie 
et al. 2004; Popat et al. 2005). 
•	People	with	increased	body	mass	index	or	
body fat are at increased risk of PD (Hu 
et al. 2006; Logroscino et al. 2007).
•	Women	occupationally	exposed	to	poly­
chlorinated biphenyls (electrical capacitance 
workers) are at increased risk of PD (Prince 
et al. 2006; Steenland et al 2006).
•	People	with	higher	educational	level	are	at	
higher risk of PD (Frigerio et al. 2005).
•	People	exposed	to	some	specific	pesticides	
have an increased risk of PD (paraquat, 
maneb, dieldrin) (Dick 2006; Drechsel and 
Patel 2008; Kamel et al. 2007). In vitro and 
in vivo laboratory animal studies of some 
specific pesticides (e.g., rotenone, paraquat, 
maneb) demonstrate toxicity to nigral 
dopaminergic neurons and reveal biologic 
mechanisms by which exposure to those 
pesticides is plausibly linked to PD risk 
(Thiruchelvam et al. 2000; Uversky 2004). 
•	People	exposed	to	some	heavy	metals	have	
an increased risk of PD (Gorell et al. 1998; 
Mergler et al. 1994).
Limited suggestive evidence of no associa-
tion. In this IOM category, evidence from 
available studies is consistent in not showing 
a positive association between exposure to a 
specific agent and a specific health outcome 
after exposure of any magnitude. A conclu­
sion of no association is inevitably limited to 
the conditions, magnitudes of exposure, and 
length of observation in the available studies. 
The possibility of a very small increase in risk 
after exposure studied cannot be excluded. 
Welding is not associated with risk of 
PD (Marsh and Gula 2006; Santamaria et al. 
2007). 
Consensus not reached on category of asso-
ciation. In this IOM category, if the entire 
committee did not agree on a conclusion, then 
the association was not assigned a category.
•	People living in rural areas have/do not 
have (Kuopio et al. 1999; Priyadarshi et al. 
2001) an increased risk of PD.
•	Vitamin E, vitamin C, and carotenoids are/
are not associated with PD risk (Etminan 
et al. 2005; Zhang et al. 2002).
•	Dietary saturated fats are/are not associated 
with risk of PD (de Lau et al. 2005; Gao 
et al. 2007; Powers et al. 2008b).
•	Well water drinking is/is not associated with 
PD risk (Kuopio et al. 1999; Priyadarshi 
et al. 2001).
•	Race/ethnicity is/is not associated with PD 
risk (Mayeux et al 1995; Van den Eeden 
et al. 2003; Zhang and Román 1993). 
Research Needs
•	Well­designed case­control studies with suf­
ficient power are needed—perhaps through 
consortia or multicenter—as well as strict 
attention to bias and confounding.
•	Consider the question of appropriate con­
trol groups. Consider alternatives to tradi­
tional sources of controls used in the past 
such as random digit dialing and centers for 
Medicare and Medicaid services, as these 
sources are now often impractical because 
of privacy and other considerations.
•	PD registries, particularly inclusive, legally 
mandated, population­based registries, are 
essential to description of demographic, geo­
graphic, and temporal patterns and trends. 
•	Diagnostic criteria for cases need to be well 
defined in studies. Criteria and disease defi­
nition may vary depending on the specific 
hypothesis being tested. Similarly, charac­
terization of clinical features is critical. Some 
risk factors may be specific for classic PD, Bronstein et al.
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whereas others may be common for all types 
of parkinsonism. 
•	Biomarkers of disease are needed, beginning 
with early stages. 
•	More	consistent	attempts	are needed to 
look at both susceptibility genes and envi­
ronmental agents in combination.
•	Better	measures	of	the	exposures	of	interest 
are needed.
Research Questions
In addition to known risk factors for PD, 
conference participants identified a number of 
others in need of further investigation. Even 
for those that are well established, however, 
there is a need for additional information 
about mechanisms by which they influence 
PD risk. Moreover, in addition to individual 
risk factors, conference participants recog­
nized a need for further understanding of 
how risk factors interact as they contribute to 
the multiple pathogenic pathways that may 
ultimately result in PD.
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